Neuro-Ophthalmic Findings in the Visual Variant of Alzheimers Disease
Ophthalmology 111:376-381, Lee,A.G. &Martin,C.O., 2004
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Low Body Weight in Alzheimer's Disease is Associated with Mesial Temporal Cortex Atrophy
Neurol 46:1585-1591, Grundman,M.,et al, 1996
Rapidly Progressing Atrophy of Medial Temporal Lobe in Alzheimer's Disease
Lancet 343:829-830, Jobst,K.A.,et al, 1994
Phenotype of Chromosome 14-Linked Familial Alzheimer's Disease in a Large Kindred
Ann Neurol 36:368-378, Lampe,T.H.,et al, 1994
Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
The Older Driver, Clinical Assessment and Injury Prevention
Arch Int Med 152:735-740, Underwood,M., 1992
Murder, Insanity, and Medical Expert Witnesses
ARch Neurol 49:608-611, Ciccone,J.R., 1992
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
The Human Kluver-Bucy Syndrome
Neurol 33:1141-1145, Lilly,R.,et al, 1983
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Capgras Syndrome:A Reduplicative Phenomenon
Neurol 29:334-339, Alexander,M.P.,et al, 1979
Clinical Neuropathological Conference
(Ed) , Dis Ner Sys 34:124, 1973, Pick's Disease., Aronson,S.&Aronson,B., 1973
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia
JAMA 314:1242-1254, Cummings, J.L.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Visuoperception Test Predicts Pathologic Diagnosis of Alzheimer Disease in Corticobasal Syndrome
Neurol 83:510-519, Boyd, C.D.,et al, 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Visuospatial deficits in posterior cortical atrophy: structural and functional correlates
JNNP 83:860-863,855, Andrade, K.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012